High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 788-793

  Mounier, Nicolas ^a   Canals, Carmen ^b   Gisselbrecht, Christian ^c   Cornelissen, Jan ^d   Foa, Roberto ^e   Conde, Eulogio ^f   Maertens, John ^g   Attal, Michel ^h   Rambaldi, Alessandro ⁱ   Crawley, Charles ^j   Luan, Jian Jian ^k   Brune, Mats ^l   Wittnebel, Sebastian ^m   Cook, Gordon ⁿ   van Imhoff, G W ^o   Pfreundschuh, Michael ^p   Sureda, Anna ^j,q   Castagna, L ^r   Russell, N H ^s   Colombat, P ^t   Richardson, D ^u   Polreicht, D ^v   Tilly, H ^w   Sutton, L ^x   Carreras, E ^y   Blaise, D ^z   McQuaker, G ^aa   Peniket, A ^ab   Gramatzki, M ^ac   Milpied, N ^ad   Cortelazzo, S ^ae   Bosi, A ^af   Irrera, G ^ag   Janssen, J ^ah   Passweg, J ^ai   Bacigalupo, A ^aj   Schattenberg, A ^ak   Mohty, M ^al   Cortelezzi, A ^am   Bay, J O ^an   Lenhoff, S ^ao   Volin, L ^ap   Cassuto, J P ^a   Duarte, R F ^aq   Gribben, J ^ar   Michieli, M ^as   Veelken, J H ^at   Poire, X ^au   Petersen, E ^av   Baccarani, M ^aw   McMullin, M F ^ax   Jantunen, E ^ay   Leyenburg, ^az   Schouten, H ^ba   Wandt, H ^bb   Bourjuis, J H ^m   Caballero, D ^bc   Martelli, M F ^bd   Bron, D ^be   Biron, P ^bf   Sureda, A ^q   Craddock, C ^bg   Masszi, T ^bh   Bailly, B ^bi   Thompson, K ^bj   Alegre, A ^bk   Blesing, N E ^bl   Nagler, A ^bm   Hall, R ^bn   Sengeloev, H ^bo   Deconinck, E ^bp   Guilhot, F ^bq   Ifrah, N ^br   Koza, V ^bs   Besalduch, J ^bt   more..

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b EBMT Lymphoma Working Party   (Spain)

^c SAINT LOUIS HOSPITAL   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h CHU PURPAN   (France)

ⁱ OSPEDALI RIUNITI   (Italy)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

^k SORBONNE UNIVERSITÉ   (France)

^l SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ St James's Institute of Oncology   (United Kingdom)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^p SAARLAND UNIVERSITY   (Germany)

^q HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^r HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^s NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^t CHU BRETONNEAU   (France)

^u SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^v CHARLES UNIVERSITY   (Czech Republic)

^w CENTRE HENRI BECQUEREL   (France)

^x CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^y HOSPITAL CLÍNIC   (Spain)

^z U Transplant et de Therapie Cell   (France)

^aa Bone Marrow Transplant Unit   (United Kingdom)

^ab Department of Haematology ^*  (United Kingdom)

^ac Division of Stem Cell Transplantation and Immunotherapy   (Germany)

^ad BORDEAUX UNIVERSITY HOSPITAL   (France)

^ae San Maurizio Hospital   (Italy)

^af CAREGGI UNIVERSITY HOSPITAL   (Italy)

^ag Azienda Ospedaliera   (Italy)

^ah VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^ai UNIVERSITY HOSPITAL BASEL   (Switzerland)

^aj UNIVERSITY OF GENOA   (Italy)

^ak RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^al NANTES UNIVERSITY HOSPITAL   (France)

^am FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^an Service D'Hématologie Clinique Adulte et Pédiatrie   (France)

^ao LUND UNIVERSITY HOSPITAL   (Sweden)

^ap HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^aq HOSPITAL DURAN I REYNALS   (Spain)

^ar ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^as CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^at LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^au CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^av UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^aw UNIVERSITY OF BOLOGNA   (Italy)

^ax BELFAST CITY HOSPITAL   (United Kingdom)

^ay KUOPIO UNIVERSITY HOSPITAL   (Finland)

^az Haga Hospital   (Netherlands)

^ba MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^bb KLINIKUM NÜRNBERG   (Germany)

^bc HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^bd Istituto di Ematologia   (Italy)

^be JULES BORDET INSTITUTE   (Belgium)

^bf CENTRE LÉON BÉRARD   (France)

^bg QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^bh Szent Laszlo Hospital   (Hungary)

^bi ERASME HOSPITAL   (Belgium)

^bj UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^bk HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^bl GREAT WESTERN HOSPITAL   (United Kingdom)

^bm SHEBA MEDICAL CENTER   (Israel)

^bn ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^bo University of Copenhagen   (Denmark)

^bp UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^bq POITIERS UNIVERSITY HOSPITAL   (France)

^br ANGERS UNIVERSITY HOSPITAL   (France)

^bs CHARLES UNIVERSITY   (Czech Republic)

^bt HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

more..

Author keywords

Aggressive B cell lymphoma; Anti CD20 monoclonal antibody; Stem cell transplantation

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 84859878294     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.010     Document Type: Article

References (13)

1. Coiffier B., Thieblemont C., Van Den Neste E., et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
2. Sehn L.H., Berry B., Chhanabhai M., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
3. +B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
4. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
5. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
6. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
7. Vignot S., Mounier N., Larghero J., et al. High-dose therapy and autologous stem cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls. Cancer 2007, 109:60-67.
8. +NHL: a prospective randomized HOVON trial. Blood 2008, 111:537-543.
9. Thieblemont C., Briere J., Mounier N., et al. The germinal center (GCB)/activated B-cell (ABC) subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL): the Bio-CORAL study. J Clin Oncol 2011, 29:4079-4087.
10. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
11. Sirvent A., Dhedin N., Michallet M., et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010, 16:78-85.
12. van Kampen R.J., Canals C., Schouten H.C., et al. Allogeneic stem cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011, 29:1342-1348.
13. Thieblemont C., Gisselbrecht C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep 2009, 11:386-393.